JIDEYTRO Drug Patent Profile
Which patents cover Jideytro, and what generic alternatives are available?
Jideytro is a drug marketed by Nuvalent and is included in one NDA. There are four patents protecting this drug.
The generic ingredient in JIDEYTRO is zidesamtinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the zidesamtinib profile page.
DrugPatentWatch® Generic Entry Outlook for Jideytro
Jideytro will be eligible for patent challenges on July 22, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 30, 2042. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for JIDEYTRO?
- What are the global sales for JIDEYTRO?
- What is Average Wholesale Price for JIDEYTRO?
Summary for JIDEYTRO
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in JIDEYTRO? | JIDEYTRO excipients list |
| DailyMed Link: | JIDEYTRO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for JIDEYTRO
Generic Entry Date for JIDEYTRO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for JIDEYTRO
JIDEYTRO is protected by four US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of JIDEYTRO is ⤷ Start Trial.
This potential generic entry date is based on patent 12,043,626.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-001 | Jul 22, 2026 | RX | Yes | No | 12,054,498 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-002 | Jul 22, 2026 | RX | Yes | Yes | 12,054,498 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-001 | Jul 22, 2026 | RX | Yes | No | 12,043,626 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for JIDEYTRO
When does loss-of-exclusivity occur for JIDEYTRO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 22357554
Patent: SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 31813
Patent: FORMES SOLIDES, COMPOSITIONS PHARMACEUTIQUES ET PREPARATION DE COMPOSES ETHER MACROCYCLIQUES HETEROAROMATIQUES (SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS)
Estimated Expiration: ⤷ Start Trial
China
Patent: 8234725
Patent: 杂芳族大环醚化合物的固体形式、药物组合物及制备 (Solid forms of heteroaromatic macrocyclic ether compounds, pharmaceutical compositions and preparation)
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 08844
Patent: FORMES SOLIDES, COMPOSITIONS PHARMACEUTIQUES ET PRÉPARATION DE COMPOSÉS ÉTHER MACROCYCLIQUES HÉTÉROAROMATIQUES (SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS)
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 1444
Patent: צורות מוצקות, תכשירים פרמצבטיים והכנת תרכובות אתר הטרואו-רומטיות מאקרוציקליות (Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds)
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 24537795
Patent: ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 24003738
Patent: FORMAS SOLIDAS, COMPOSICIONES FARMACEUTICAS Y PREPARACION DE COMPUESTOS DE ETER MACROCICLICO HETEROAROMATICO. (SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS.)
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 240087788
Patent: 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 2320768
Patent: Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering JIDEYTRO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2021268664 | ⤷ Start Trial | |
| Brazil | 112022022535 | COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO DE CÂNCER, MÉTODO DE INIBIÇÃO SELETIVA, MÉTODO DE REDUÇÃO DE UM NÍVEL DE ROS1 OU ALK | ⤷ Start Trial |
| Canada | 3179700 | AGENTS CHIMIOTHERAPEUTIQUES A BASE D'ETHERS MACROCYCLIQUES HETEROAROMATIQUES (HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |

